Question 1

What are the side effects of Dihexa?

Accepted Answer

None are reported in the abstracts of the studies behind this page, and that sentence needs reading carefully. These experiments were set up to find out whether Dihexa helped memory or nerve repair. They were not set up to look for harm, and most do not say whether they checked. The 2024 rat study comes closest to a general check: animal body weight, motor function, and cognitive abilities were measured for five weeks, before euthanasia and histopathological analysis, meaning the brains were examined under a microscope. Those rats were also given a brain toxin, so any change in weight or movement had two possible causes, and the abstract does not separate Dihexa's own effect on weight from the toxin's. What a reader can take away is narrow. No side effect is described, and none of these studies was designed to find one, so the honest answer is that the side effects of Dihexa are unknown rather than absent.

Question 2

Is Dihexa peptide safe?

Accepted Answer

That cannot be answered from the published research, and any page that answers it with a yes is going beyond the studies. Even the largest summary of this work, a 2018 systematic review, was a systematic review of experimental (non-human) studies assessing cognitive effects of RAS peptides, the hormone family Dihexa comes from. It looked at memory, in animals. A safety verdict needs something different: people, a control group, a list of what went wrong, blood tests, and enough time for slow problems to show. None of that appears among the studies we could find for Dihexa. There is no human dose, no human blood level, and no record of a single person's reaction. The absence of reported harm in a literature that never measured harm says nothing about whether harm occurs, and that is the most useful sentence on this page for anyone deciding what to do.

Question 3

Could Dihexa encourage cancer growth?

Accepted Answer

This is the concern raised most often, and it comes from the mechanism rather than from any finding. Dihexa is meant to switch on hepatocyte growth factor and its receptor, Met, also written c-Met. A 2019 review from cancer research notes that HGF acts via the Met receptor and has also received research attention with ongoing efforts to develop treatments to block the Met receptor and its signal transduction pathways. A 2010 study found that norleual, a blocker from the same chemical family, suppressed pulmonary colonization by B16-F10 murine melanoma cells, mouse skin-cancer cells with an overactive HGF/c-Met system, in the lungs of mice. A 2011 paper argued that molecules targeting the dimerization domain of HGF may represent novel and viable anticancer therapeutic agents; that paper has since been retracted. Dihexa was built to do the opposite of those blockers. None of the studies behind this page tested it on a tumour, in an animal or a dish, so the risk is neither a demonstrated one nor a dismissed one. It is an open question that sits squarely on the receptor the compound was designed to target.

Question 4

What did the animal studies actually watch for?

Accepted Answer

Mostly the thing they hoped to improve. That is normal for early research, but it leaves a reader with a record of benefits measured and harms unmeasured. In the 2021 nerve study, limb sensory and motor functions were assessed at 1-2 week intervals post nerve repair until the study endpoint (16 weeks), which is careful follow-up of recovery rather than of side effects. In the 2021 Alzheimer-model mouse study, the researchers looked inside the brain and report that Dihexa decreased the activation of astrocytes and microglia, the brain's support and immune cells, in the mice. Lower activity in those cells was read as a benefit, since they drive inflammation in this model. It also shows that Dihexa changed the behaviour of cells other than neurons, and none of the abstracts reports blood counts, organ weights or liver and kidney tests, which are the usual first screens for harm.

Question 5

Is it safe to take Dihexa every day?

Accepted Answer

No study among these sources asked that question in any form a person could use. The closest thing is how long animals were exposed. The longest Dihexa exposures in the record are five weeks in rats given a brain toxin and sixteen weeks in rats recovering from nerve surgery. How often those animals were dosed, and by what route, is laid out on the Dihexa dosage page. Neither study counted side effects as an outcome, so the length of exposure tells a reader how long animals lived with the compound rather than how well they tolerated it. The best long-exposure data in this family belong to the parent hormone fragment: a 2025 mouse study used osmotic minipumps to administer AngIV in mice continuously over 4 weeks. Five weeks in a rat alongside a toxin, and four weeks of a different molecule in mice, do not describe months of daily use in a healthy adult. That gap is the answer: the animal record does not tell a reader anything about taking Dihexa every day.

Question 6

Does Dihexa affect blood pressure or blood clotting?

Accepted Answer

Dihexa belongs to the angiotensin family, and angiotensin is best known as a blood pressure hormone, so the question is fair. A 2019 review notes that the angiotensin II (AngII)/AT1 receptor system is best known for mediating blood pressure and body water/electrolyte balance. Dihexa comes from a different piece, angiotensin IV, which works through different receptors. None of the studies behind this page measured blood pressure in an animal given Dihexa. On clotting, the 2025 mouse study of the parent fragment found that AngIV treatment did not induce thrombus formation in the heart, did not affect platelet numbers, and did not enhance platelet aggregation. Thrombus means a blood clot, and platelets are the cells that start one. That result is reassuring for angiotensin IV in mice, but it was not a study of Dihexa, and a compound built to last longer in the body cannot be assumed to behave like the fragment it was made from.

Question 7

Is Dihexa hard on the liver or kidneys?

Accepted Answer

There is no liver or kidney test of Dihexa among the studies we could find, in any species. The liver does come up, but in an unexpected way. In stem cell biology, a 2022 study found that combining Vitamin C, Dihexa, and Forskolin (VDF) could substitute growth factors to induce hepatic specification, meaning it helped steer human stem cells toward becoming liver cells in a dish. That shows Dihexa is active on cells that can become liver tissue, which fits a molecule built to mimic a growth factor first named for its effect on liver cells. It does not tell a reader whether Dihexa strains, protects or does nothing to an adult liver. A lab recipe for growing cells and a test of organ function are different things, and only the first exists here in print. For the kidneys there is nothing at all among these sources.

Question 8

What does Dihexa interact with?

Accepted Answer

No interaction has been studied in a person. The only drug combinations in this record come from the zebrafish hearing work, where Dihexa was given alongside two antibiotics and several research inhibitors. In those larval fish, pretreatment with Dihexa does not affect the amount of fluorescently tagged gentamicin that enters hair cells, so it did not seem to block the antibiotic from reaching its target. The same study found that Dihexa's robust protection is partially attenuated by co-treatment with inhibitors of the downstream HGF targets Akt, TOR and MEK, three signalling switches inside the cell. Drugs that block those switches exist in medicine, so the finding hints that such drugs could blunt whatever Dihexa does. It is one fish experiment, measured on hair cells, and it is not evidence about what happens when a person combines Dihexa with anything.

Question 9

Does purity matter for a molecule this small?

Accepted Answer

More than for most compounds, according to the one study that tested a near relative. In the zebrafish work, addition of an amino group to the N-terminal of Dihexa also attenuates the protective response, suggesting that even small substitutions greatly alter the specificity of Dihexa for its target. An amino group is a few atoms. Adding it changed how well the molecule worked. The 2013 rat paper that produced Dihexa makes the same point from the other side, reporting that several N- and C-terminal modifications lead to dramatically improved stability in the molecules it tested. Small changes at either end of this molecule change what it does and how long it lasts. A batch that is slightly wrong at one end may not be a weaker version of Dihexa but a different compound. None of the studies behind this page tested material sold under the name, so there is no measured purity to report.

Question 10

Who was left out of the studies?

Accepted Answer

Everyone a reader might worry about, starting with people. The animals that were studied were a narrow group. The 2024 study used forty male Wistar rats, a standard laboratory strain. The nerve study gave its treatments to male Lewis rats, another laboratory strain. The memory work used aged rats and mice bred for Alzheimer-like changes, and the hearing work used fish larvae a few days old. In the two studies that state sex, every animal was male. So among these sources there are no females, no pregnancy, no young animals given repeated doses, and no animals with heart, liver or kidney disease. Those are the groups a safety record normally checks first, and none of them was ever asked about here in print. The absence of a warning for any of them is not a finding about any of them.

Question 11

Does the retraction change the safety picture?

Accepted Answer

It cuts both ways, which is why it belongs on a safety page. The retracted 2014 paper reported that dihexa and its parent compound induce c-Met phosphorylation in the presence of subthreshold concentrations of HGF, meaning it helped small amounts of the growth factor switch the receptor on. That was the main published evidence tying Dihexa to the growth receptor behind the cancer concern above. A second paper in the same programme, on Development of Angiotensin IV Analogs as Hepatocyte Growth Factor/Met Modifiers, J Pharmacol Exp Ther, 340: 539-548, drew a notice of concern in 2021 and was later withdrawn. With those papers gone, the evidence that Dihexa acts on the growth receptor is weaker. That weakens the cancer worry, and it weakens the explanation for any benefit by exactly the same amount. Neither change makes the compound better understood, and a reader should regard both its promise and its risks as less mapped than they appeared before 2021.

Question 12

Why is the Dihexa harm record this thin?

Accepted Answer

Because the work stopped before the stage where harm is measured. The developers' 2015 review describes the goal as small molecule AngIV-based compounds that are metabolically stable, penetrate the blood-brain barrier, and facilitate compromised memory and motor systems. An earlier review from the same field frames the work the same way, discussing the development of efficacious AngIV analogs tested in animal models of Alzheimer's and Parkinson's disease. Every step described is about whether the molecule works. Safety work usually comes later, once a molecule looks worth the time and the cost. Among the research behind this page, that later stage never comes: there is no study built to find a harmful amount, no study that tries it in people, and no trial. What a reader has is efficacy work in animals with a safety gap behind it, and the gap is a measure of how early the compound is rather than of how dangerous it is.

Dihexa side effects and safety data